Nectar Social | $10,600,000 | (Jun 6, 2025)
Baobab | $13,702,071 | (Jun 6, 2025)
Signify Bio | $15,000,000 | (Jun 6, 2025)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Voltrac | $2,286,772 | (Jun 6, 2025)
Rosebud | $6,000,000 | (Jun 6, 2025)
Allay Therapeutics | $57,500,000 | (Jun 6, 2025)
Impart Security | $12,000,000 | (Jun 6, 2025)
Flank | $10,000,000 | (Jun 6, 2025)
Obvio | $22,000,000 | (Jun 5, 2025)
Filament Syfter | $4,800,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)